Abstract | OBJECTIVES: MATERIALS AND METHODS: 21 patients with newly diagnosed HNSCC were included. Radiation therapy was planned to a dose of 66 Gy/33 fractions. Doses of cisplatin and gefitinib were kept constant at 30 mg/m(2) and 250 mg respectively. Dose of weekly docetaxel started with 5 mg/m(2) and escalated 5 mg/m(2) up to a maximum of 20 mg/m 2 . Serious adverse event was defined as grade 3/4 hematological and non-hematological toxicities. RESULTS: All patients (three in dose level 1 [5 mg/m(2)], level 2 [10 mg/m(2)] and level 3 [15 mg/m(2)]) did not experience any hematological serious adverse events. Weekly docetaxel of 20 mg/m(2) could not be tolerated with the combination, and we encountered two hematological ( neutropenia) serious grade 4 adverse event and one grade 3 mucositis at level 4. Six patients were treated by omitting week 3 chemotherapy reducing the number of weekly cycles to a minimum of four. Gefitinib was continued throughout the treatment period. All patients tolerated the treatment well although with grade 2 hematological/non hematological toxicities. CONCLUSION:
|
Authors | Prasad Eswaran, Kumaravelu S Azmi |
Journal | Journal of cancer research and therapeutics
(J Cancer Res Ther)
2013 Jul-Sep
Vol. 9
Issue 3
Pg. 392-6
ISSN: 1998-4138 [Electronic] India |
PMID | 24125972
(Publication Type: Journal Article)
|
Chemical References |
- Quinazolines
- Taxoids
- Docetaxel
- Cisplatin
- Gefitinib
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(pathology, therapy)
- Chemoradiotherapy
(adverse effects)
- Cisplatin
(administration & dosage)
- Docetaxel
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Female
- Gefitinib
- Head and Neck Neoplasms
(pathology, therapy)
- Humans
- Male
- Middle Aged
- Quinazolines
(administration & dosage)
- Squamous Cell Carcinoma of Head and Neck
- Taxoids
(administration & dosage)
- Treatment Outcome
|